- Home
- FSEA vs IMMX Comparison
FSEA vs IMMX Comparison
Compare FSEA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- IMMX
- Stock Information
- Founded
- FSEA 1890
- IMMX 2014
- Country
- FSEA United States
- IMMX United States
- Employees
- FSEA N/A
- IMMX N/A
- Industry
- FSEA Savings Institutions
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- FSEA Finance
- IMMX Health Care
- Exchange
- FSEA Nasdaq
- IMMX Nasdaq
- Market Cap
- FSEA 52.6M
- IMMX 50.1M
- IPO Year
- FSEA N/A
- IMMX 2021
- Fundamental
- Price
- FSEA $11.28
- IMMX $2.34
- Analyst Decision
- FSEA
- IMMX Strong Buy
- Analyst Count
- FSEA 0
- IMMX 1
- Target Price
- FSEA N/A
- IMMX $7.00
- AVG Volume (30 Days)
- FSEA 19.2K
- IMMX 360.1K
- Earning Date
- FSEA 05-09-2025
- IMMX 06-10-2025
- Dividend Yield
- FSEA N/A
- IMMX N/A
- EPS Growth
- FSEA N/A
- IMMX N/A
- EPS
- FSEA 0.00
- IMMX N/A
- Revenue
- FSEA $16,196,000.00
- IMMX N/A
- Revenue This Year
- FSEA N/A
- IMMX N/A
- Revenue Next Year
- FSEA N/A
- IMMX N/A
- P/E Ratio
- FSEA $1,388.83
- IMMX N/A
- Revenue Growth
- FSEA 97.61
- IMMX N/A
- 52 Week Low
- FSEA $8.60
- IMMX $1.26
- 52 Week High
- FSEA $11.80
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- FSEA 52.51
- IMMX 61.49
- Support Level
- FSEA $11.04
- IMMX $1.89
- Resistance Level
- FSEA $11.50
- IMMX $2.50
- Average True Range (ATR)
- FSEA 0.24
- IMMX 0.17
- MACD
- FSEA 0.00
- IMMX 0.00
- Stochastic Oscillator
- FSEA 48.00
- IMMX 73.77
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.